Faeth Therapeutics Inc (FTH) 13F Positioning & Ownership Changes (Q2 2026)

FTH ranks #6440 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

FTH is a top-conviction position for B Group, Inc. — at 7.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in FTH belongs to Montanova Capital, LLC, but the position matters far more to B Group, Inc., who has 7.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Morgan Stanley has added to its FTH position for two straight quarters, increasing it by $433.1K to reach $433.2K today.

FTH is down 4.5% today, but institutions show net buying of $293.8M this quarter — a divergence between today's price move and the underlying institutional flow.

FTH reported a net loss of $21.1M in its latest fiscal year.

• Not yet profitable — net loss of $21.1M in the latest fiscal year
• Net income improved year over year, from -$30.2M to -$21.1M
• Operating cash flow was negative, using $20.5M in cash
• Current ratio of 5.06x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.23x equity — within a conventional range